Uncategorized

Gold and Gold-Copper-Silver Values Are Looking Prime For The Picking

October 29, 2017 by Staff Editor

Here’s something all investors looking at gold and gold opportunities should know: The gold mining industry is seriously depleting its reserves, not finding new deposits fast enough to keep up, and could now be on the verge of the most profitable turning point in decades.

The climate for gold is looking stronger as world tensions rise and small cap mining companies are falling into favor again. Our eyes are on those companies seeking secure gold resources; in this case Lucky Minerals Inc. (TSX.V: LJ) (OTC: LJMHF) for its gold-copper-silver project in the western US state of Montana. Based on gold’s current moves, Lucky Minerals deserves investors’ attention now.

According to analysis by BMO Capital Markets and Bloomberg, the gold mine supply will peak in 2019 and continue falling through at least 2025 (1).

Large producers such as Barrick (NYSE:ABX), Goldcorp (NYSE:GG), Newmont (NYSE:NEM) and Kinross (NYSE:KGC) are focusing directly on the Western United States to provide new supplies. These and many other companies have made new investments there, and are now searching for additional lucrative projects.

Clearly these investments are being focused on what is a stable political and operating environment. This makes for an interesting M&A climate and some exceptional opportunities for junior mining companies.

For our readers the equation is simple: scout out the best values in secure mining regions with new or developing gold and gold-copper-silver projects, get on board now and watch for momentum as reserves run down and/or gold rallies.

Lucky Minerals, whose Emigrant gold project is forming into what could be a 1 to 2 billion tonne deposit in the heart of Montana, could easily be one of the best targets we’ve located.

New Gold Projects are Being Very Well Rewarded.

New gold projects with real merit, including significant size and development potential, are seeing rich rewards. For example, investors turned $200 million to $2.3 billion with Fronteer Gold, a Nevada junior exploration company acquired by Newmont Mining in 2011. Endeavour Mining purchased True Gold for U$190 million in 2016.(2)

The successful mining companies locate deposits, drill them off, remove the risks associated with the early stages and then sell or develop them to the mining production stage. Nearly all major discoveries in the western United States that have followed this formula have found solid support and been rewarded greatly.

The market for gold has been marching higher since early September and has climbed to over a 5-month high recently. Now, the tempo of investment is stepping up markedly.

The consensus appears to hold that considering the overall market, the current gold rally seems well supported. And here’s where juniors can really rule the day.

You Could BUY a Junior Gold Mining Stock at Pennies a Share – See Our Recommendation

Montana Is an Ideal Spot for Mining

Montana has long been home to some very successful mining companies.

The state is 8th in total gold production out of all the western states, including Nevada. Mining is the state’s 6th largest employer. It has a solid, capable mining work force. It is amenable to mining practices with reasonable regulation, and it has a strong record for accommodating mining exploration.

More than anything, Montana offers a rock stable political climate.

All these factors play heavily into junior mining companies like Lucky Minerals being able to operate successfully at a small scale and then grow to become large plays.

If it’s ease of access, reasonable environmental practices, solid economics and political stability that companies seek, then Montana is a Triple A mining location.

There are a number of successful Montana mining companies who live by the state’s strong mining provisions including Montana Tunnels; Placer Dome Inc. and Stillwater Mining Company to name a few.

This is the vicinity where Lucky Minerals has located its’ stake in the Emigrant Mining District, which the U.S. Geological Survey includes as one of the world’s giant porphyry systems in its’ report and global database.

Lucky Mineral’s Emigrant Creek Montana Project

Lucky Mineral’s formula is relatively simple: acquire a potentially large gold-copper-silver trend in the Western US, re-interpret historical drilling data into a new target model and then drill out the discoveries in a higher priced gold market, not overspending or over extending themselves.

This could be compared to several Montana mining companies with major projects including New Gold’s Afton Mine, Aurico Metals’ Kemess underground projects, and Rio Tinto/ BHP Billiton’s Resolution Copper Mine, among others.

Lucky Mineral’s exploration focus is a historic deposit located at Emigrant Creek in southern central Montana. The property is comprised of about 15 square kilometers (6 square miles) and situated around some historic 68-hole drill program areas that Lucky now holds in a large database.

In all, about $20 million has been spent on developing the drilling, IP surveys, assays and various techniques to define and evaluate the potential deposit. Results show there are six copper-gold-silver deposits identified within the claim area, which is believed to be all part of one large porphyry (resource bearing) system.

Interestingly, the extensive drilling carried out by previous companies did not examine the entire system, since it was mostly above the copper and gold part of the system. What Lucky Mineral’s veteran mining management believes is that the higher grade metal is considered to be below the previous drilling.

Lucky Minerals is carrying out a $2.5 million drill program of its own to further define the resource.

All included, the Emigrant package of properties (nine patented claims and eight unpatented claims) that Lucky Minerals has managed to bring together holds a potential 1 to 2 billion tonne mineral asset. Lucky Minerals recently managed to amalgamate individual properties so that they can integrate them as one large asset.(4)

The property has significant reported gold and copper that’s summarized as longer intersections of lower grade gold with shorter sections of high grade gold. These are accompanied by significant amounts of copper, silver and molybdenum.

Lucky Mineral’s Emigrant Creek Property showing drill sample values of gold and copper from different areas.

As you would imagine, the Emigrant Creek Project has been well thought out with easily access by road, close proximity to rail for shipping product to smelters in Utah and Arizona, access to major water and power within 20 kilometers and access to major infrastructure about 50 km away in Livingston, Montana.

Look for a Gold-Copper-Silver Mining Stock That Could Return 10x, 20x or more! – See Our Recommendation

Getting in at the Earliest Stage with Junior Miners

Market watchers and analysts suggest putting roughly 20% of your gold into the hard asset. That’s a great strategy if you believe in the yellow metal.

But they also suggest getting in at the source, with the gold miners and here’s where the juniors shine. For truly large returns (10x, 20x etc.), we seek out early stage companies with the potential for massive assets. These are nearly always junior mining companies, as with Lucky Minerals Inc.

We favor juniors for their record returns and ability to leverage pure plays. Juniors can go all-in for exploration at lower costs and pull back as needed to preserve capital. The large diversified miners rarely have this luxury, so they don’t often create new discoveries or turn old ones into major plays.

Backing juniors means more risk than the BIG mining companies. But that hasn’t deterred those investors who have doubled, tripled or quadrupled their returns on early stage gold projects.

It’s certain that Lucky Minerals is a junior mining company that has put itself in the lead position of what could be a very big project that if not brought to production, could make an excellent buy-out target for major players, and an even greater potential pay-off.

FEATURE STOCK: FOR COMPARISON

[table id=20 /]

Gold Group Winners: Too Late for Major Gains, But Still Good to Compare

These gold mining companies (mining for gold/copper/silver etc.) have been increasing their efforts over the past year. The market has been marching higher since early September and has climbed to over a 5-month high recently.(3) We’ve posted the leaders in mining that have vast gold interests, many in the Western United States. These are big board stocks with massive share caps, so they are not likely to see the potential rise in value that are possible with junior miners. They are established gold miners to model after in the mining space.

[table id=19 /]

Our Recommendation: We Give Lucky Minerals Our Best Value BUY Rating

If gold deserves your attention, then Lucky Minerals should front and center right now.

The dark characters, like North Korea and Russia have gotten bolder. China has upped its’ game. The US no longer runs unquestioned as the world’s most powerful and influential country. All these factors lead to the potential for war, or at least the highest level of conflict, at the most likely point in decades.

Global governments have taken to printing money as a means to further economic growth. Central banks have lowered interest rates to insanely low levels, even dipping into the negative.

Britain’s “Brexit” now raises serious questions about the viability of even the European financial system. People are even asking “Will the euro survive?”.

At the same time, governments around the globe are devaluing their currencies on purpose and in some cases, unintentionally.

This is the exact environment in which precious metals offer their best value.

We see this in the movement of the currencies and as evidenced, gold is outperforming stocks.

That’s good for gold mining companies across the board, but it’s especially true for our favored junior miners. When gold rises, those companies that are leveraged to the price of the commodity rise much higher. It’s simple math.

It’s happened plenty. For example, the Market Vectors Junior Gold Miners ETF (NYSE: GDXJ)(5) rose 183% in a single six-month period in 2016. It then went on a 30% run from May to September of 2017.

Given the landscape, we believe Lucky Minerals is located in one of the most politically stable and secure gold mining regions in the world. But that’s not the only reason for to investors to consider this play.

The Emigrant Mineral Trend is potentially very large and could put Lucky Minerals on top of 1 to 2 billion tonnes of economic gold, copper, silver and molybdenum. If the Emigrant mineral structure connects at a lower depth as the company suspects, this could be an extremely viable domestic gold-copper-silver play that rivals the best mining operations in the region.

This situation is still relatively early stage, so Lucky Mineral’s stock trades at just pennies per share.

It’s likely that gold investors will see the data and heed the call. Many are already on this trend and seeking to capture the best values. Others may watch it pass by thinking that gold reserves will somehow be restored. That’s unlikely.

We foresee a coming gold rally that will fuel this end of the market. When junior miner companies do strike, they strike BIG, with stock valuations that shoot up by factors of 10.

Gold offers security on many levels and we look for junior miners, and especially developing US players to lead the market trend.

USA News Group
Editorial Staff

Sources:

(1) BMO Markets – Bloomberg: https://www.bloomberg.com/news/articles/2016-12-21/gold-miners-are-running-out-of-metal-five-charts-explaining-why

(2) Endevour Buys True Gold – https://beta.theglobeandmail.com/report-on-business/industry-news/energy-and-resources/endeavour-mining-reaches-deal-to-acquire-true-gold-and-new-african-gold-mine/article29029512/?ref=https://www.theglobeandmail.com&

(3) Gold Reaches High – https://markets.businessinsider.com/news/stocks/Canadian-Stocks-Are-Up-Slightly-As-Gold-Stocks-Shine-Canadian-Commentary-1002946369

(4) Lucky Minerals – https://www.luckyminerals.com

(5) Gold Miners ETF – https://finance.yahoo.com/quote/GDXJ/profile?p=GDXJ

Disclaimer

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USAnewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lucky Minerals Inc. (“LJ”) advertising and digital media. There may be 3rd parties who may have shares of LJ, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group does not own any shares of LJ.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

There are Real Opportunities for Huge Profits in Mobile Gaming –If You Are Willing to Seek Out the Pokémon

October 23, 2017 by Staff Editor

Just when you might think that the video and mobile game space has lost its mojo, along comes a Candy Crush or Pokémon Go game that sends its developer’s stock soaring.

Together, those two mobile game properties managed to generate a massive $2.5 billion in revenue and made a lot of investors wealthy. And there are plenty more where that came from.

The shift to mobile gaming has opened the door for savvy companies that understand how to monetize mobile games and generate hit gaming properties.

We’ve discovered just such an operation in Tapinator, Inc. (OTC: TAPM), an innovative young company that has positioned itself for success at the forefront of mobile gaming.

This is a stock poised for moves now. We are convinced it is severely undervalued and investors can take advantage of the lull that has left most reviewers focused on other tech stocks.

We break out the company in some detail, but we believe that this is an easy double or triple based on its current position and potential for major upside using a solid formula that’s already put Tapinator, Inc. on track for major growth and revenues.

Mobile Gaming Success Is About Pigs and Chickens

If you were one of the 8+ million players who downloaded and played the wildly popular mobile game Farmville on a phone or tab, you understand how to run a farm.

Creating a successful mobile gaming company is a lot like that; in order to be really successful, you need pigs and chickens.

You need chickens to lay eggs every single day. Chickens are cheap and expendable. They constantly produce food and support the farm’s immediate needs with little care or upkeep.

Pigs, on the other hand, take time and real effort to raise. They require constant care and attention. And they are not cheap to feed. However, pigs offer the really big pay-off. One prize pig can fill the freezer for an entire winter or if sold at market, a pig can pay payback the initial investment many, many times over.

The key is having a mix of enough chickens to get to the point where you cash in a prize pig.

This is the scenario that faces nearly every mobile and video game company. They must find an effective mix between immediate revenue producing games and those marquee titles that are true company makers.

Apparently mobile gamers Tapinator, Inc. learned this lesson early on and have built a robust formula for success that is a careful balance between low-cost, rapid turnaround games and big name titles that could easily be the hit wonders of the year.

Several of their games have already earned the distinction of “New Games We Love” on the Apple iOS platform.

Finding a company in the unique position of having a history of valuable game properties and a path to develop blockbuster type franchises is rare. We urge readers to carefully consider that there are only a few public mobile gaming companies with these qualities – yet still trading at pennies per share.

For this reason, Tapinator, Inc. deserves your attention.

A Market This Size Is Worth the Effort

If you have not tracked the video and mobile gaming space recently, you may be surprised at just how large and lucrative it really is.

Video gaming has become an increasingly relevant force in entertainment and part of everyday life. From 1989 to 2013, the global video game industry, including mobile revenue, grew at a compounding annual growth rate (CAGR) of 11.3% from about $19.9 billion to $76.0 billion. (1)

That is a massive global market that has created a lot of wealth. A large part of its growth comes from the rise of new platforms with capacity for video gaming.

From arcades and consoles like the NES and the Atari, games quickly shifted to personal computers and finally, the internet which opened the way for browser-based gaming. The next step in evolution was smartphones and tablets with the ability to download video games through app stores.

Gaming is now easily accessible on a variety of platforms and as we all know, mobile games are played virtually everywhere on a 24/7 basis.

The global video game industry is projected to grow at a CAGR of 6.2% from $101.1 billion in 2016 to $128.6 billion in 2020 according to research by Newzoo, which tracks all gaming.

Mobile gaming, which refers to gaming on smart devices such as a phone or tablet, is expected to be the segment that will experience the highest growth. Newzoo’ s projections show mobile gaming revenue growing 68% from $38.6 billion in 2016 to $64.9 billion.

It would be easy to dismiss the gaming market since there are many more game flops than there are winners, but that would be a serious mistake.

The industry tailwind is with the mobile segment that Newzoo called the “most lucrative segment” of the gaming industry and predicts 19% year-over-year growth. Newzoo also says mobile gaming will represent over half of the total games market by 2020 (2).

Tapinator Inc. has the Right Mix of Games and Know How to Monetize Them

Founded in 2013, Tapinator is a mobile gaming company successfully creating gaming apps for iOS and Android. The company is based in New York with product development teams located around the world.

Its leader is visionary CEO Ilya Nikolayev, who is credited with creating one of the first successful Facebook applications. That app was eventually sold to Intelius, bringing substantial returns to early investors. Nikolayev is recognized as an industry expert. He is featured regularly on Fox Business, Bloomberg and TheStreet for his insights into the mobile gaming business.

Under his guidance, the Tapinator team has developed and published over 300 mobile gaming titles that have collectively achieved over 400 million player downloads.

That is no small feat in the highly competitive mobile game and app business.

All the hard work and perseverance has earned Tapinator a strong reputation and recognition in publications such as Forbes, Fortune, Venture Beat and The Huffington Post. The collective opinion of reviewers seems to echo our view: Tapinator is a “mobile gaming company that has found a balance between profitability and creativity.”

Again, it’s all about the mix of pigs and chickens.

Tapinator Makes Mobile Games That Make Money

Tapinator’s business strategy, which has served them well, relies on developing and publishing a continuous flow of Rapid-Launch Games at low-cost with reliable return, while developing and publishing costlier Full-Featured games that offer more in-depth content and support long-term engagement.

In order to make this formula work, their experienced team of developers, strategists and product specialists have established serious expertise in building scalable, quality gaming products across various categories. They use a proprietary set of development processes that depend upon key factors such as gaming category, estimated player retention, and projected profitability.

In other words, Tapinator knows exactly how much to put into a game in order to get the best return before they even begin.

The Company’s portfolio of over 300 mobile gaming titles generate hundreds of thousands of daily player downloads. They provide predictable and attractive returns through the sale of branded advertisements and consumer app store (“in-app”) transactions.

Tapinator’s game universe is significant. Simply search “Tapinator” in the Apple Store or Google Play Store and you’ll see the deep catalogue of choices.

The best-in-class Full-Featured Games (ie. the pigs), such as ROCKY™ and Solitaire Dash, provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns.

This is the model that creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years.

The company’s base (ie. chickens) are its Rapid-Launch Games. These are typically low-cost, quick to develop (like 90 days or so), follow a known theme and capitalize on short player engagement times.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as “New Games We Love.” Big Sport Fishing 2017 received well over 520,000 player downloads during the game’s first seven days after global release.

Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018.

The company’s Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator’s diversified revenue sources currently break out as 54 percent from advertising placed within its mobile games, and 46 percent from consumer app store (“in-app”) purchases.

For better gaming experience and engagement, Tapinator limits advertising placements to between game levels. It also runs rewarded video ad units that are tied directly into the game’s currency, again upping the in-app purchase return.

Out of Tapinator’s portfolio of more than 300 active titles, no single game accounted for more than 25 percent of total revenues during the first half of 2017. That is the result of a well-planned and carefully executed corporate strategy.

Plenty of Upside in AR (Augmented Reality) and VR (Virtual Reality)

Tapinator is a forward-looking company. They see their opportunities in Virtual Reality (VR) and Augmented Reality (AR) – two gaming areas that show great promise.

Virtual reality games are pretty straight forward, involving the player in a virtual environment, but for those unfamiliar, Augmented Reality is use of real world imagery and involvement combined with game play. The most successful AR game is Pokémon Go, which ties real GPS locations to mobile devices so players can find Pokémon characters that appear on screen in the real world.

Tapinator is already hot on this path. They have released several prototype VR games to gather data before pursuing a more significant VR product.

Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion.

Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. For instance, Tapinator is able to use its cross gaming exposure to hundreds of thousands of players without incurring marketing costs for new games. This has proved very successful.

There are also significant opportunities for expanding Tapinator’s gaming IP to new platforms like Steam and leading messaging apps on the horizon.

With no significant changes in its core development group, the company is targeting a 30% plus annual growth for 2017 to 2019.

The Moonshot Scenario

In looking at the mobile gaming space, we can’t help but mention the potential for a moonshot gaming application. It’s happened time and time again, and the companies that are successful go rocketing skyward, rewarding investors richly.

This is the scenario where a single game takes flight from the simple, every day interest level into a blockbuster title worthy of an entire franchise. These are games like AngryBirds™, CandyCrush™ and Battle of the Clans™.

This could easily be the fate of one or more of Tapinator’s gaming properties.

Remember that the little know game development companies that put those iconic titles in play were doing exactly what Tapinator is doing now; building quality game experiences guided by player engagement and variations on popular themes.

This brings up the other specter for Tapinator: acquisition.

With or without a rock star game app, smaller gaming companies can become very attractive to the big players. Leaders in this space continually look for real value in the game properties and the organizations behind them.

Tapinator is a well-run company. It has a solid history for building quality games and it has allied itself with meaningful franchises. One “winning” game property could send ripples across the industry and up the stakes immediately.

If Tapinator were to become a target for the major mobile app companies, we expect that the stock could offer returns that are 10x or even 20x its current value, based on the speculation.

FEATURE STOCK: FOR COMPARISON

[table id=27 /]

Gaming Winners: Too Late for Big Gains, But Excellent to Study

We highlight some of the biggest winners in the video and mobile industry this year to date. These are large cap stocks that have made the meteoric ride with marquee game titles and franchises that bring in hundreds of millions of dollars. They exemplify what happens when a solid gaming company with a proven formula continually produces a mix of money making games and big “hits” that drive value.

[table id=28 /]

Our Recommendation: We Give TAPM Our Strong BUY Rating

After our extensive review, we strongly believe that TAPM is one of the best mobile game companies we have encountered. We also think it is very undervalued, based on its early successes and upside potential.

TAPM’s strategy of capturing active user engagement through quality content and driving in-game purchases will continue to help the company achieve recurring and predictable cash flow on an ongoing basis.

The effectiveness of this strategy has been evident with the success and profitability of other companies with their big name titles like Activision’s Overwatch, World of Warcraft and many others.

At the same time, TAPM continues to grow its user base and solid revenue path with the low-cost, rapid turnaround games that helped to put it on the map.

Gaming companies in the mobile space have to walk a precarious line, but Tapinator, Inc. has managed to find its balance over several years. They have realized that mobile gaming is a lucrative technology- and analytics-driven business.

Photo: Tapinator, Inc.’s popular game titles include major franchises like “Rocky”

Now, they appear ready to use their proven formula to create some major successes, both in conventional gaming and the VR and AR space. Targeting 30% plus annual growth over the next two years is not unrealistic, since they have constantly reached their stated goals.

It would also not be unheard of for Tapinator’s team to come up with a blockbuster game either, since that what they are in the business to do.

If it were not for the experience of the company’s CEO Ilya Nikolayev, we might wonder if they could handle that kind of growth and expectations that places on a smaller company. But Nikolayev and the team are hardened by battle over a decade of development together. That gives us a level of confidence not found in other emerging companies.

We recommend that investors look for value in mobile apps now, while the industry is relatively quiet and plodding along with its solid 19% y-o-y growth.

Investors who are willing to seek out the unique gaming situations like TAPM may find that it can offer outstanding rewards, even if it takes as much effort as finding an elusive Venusaur, Blastoise, or Charizard in Pokémon Go. It can be worth it.

USA News Group
Editorial Staff

Sources:

(1) Video gaming market : https://newzoo.com

(2) Mobile growth: (https://dtn.fm/wBd1R).

Disclaimer

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USAnewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Tapinator, Inc. advertising and digital media. There may be 3rd parties who may have shares of TAPM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group does not own any shares of TAPM.

Small Medical Wonders Hold Promise for Big Profits

October 23, 2017 by Staff Editor

Before we discuss this major technology shift, we need to add an important footnote: the company we discuss, Imagin Medical Inc. (CSE: IME OTC: IMEXF), just announced approval of human testing for their product.

See the news release:(1)

We add this note because the news is not widely known and puts the company at a completely different stage of development.

Imagin Medical’s stock has not noticeably changed, likely because the news is so new and hasn’t been publicized except to peers in the medical industry.

Companies in the unique position of being in clinical testing with a breakthrough product who are virtually unknown don’t come along every day. We urge our readers to carefully consider that there are few public medical companies this operationally advanced – including in human testing with a fully patented medical system – but trading at pennies per share.

Imagin Medical is a Revolution in The Making

Can you remember the last time you watched a low-res, cathode ray TV? You might or you may be too young to have even experienced that ancient technology. But you certainly can remember experiencing the clarity and detail that came to life when you saw your first HD movie on a 1080i flat screen… and perhaps more recently when you saw an Ultra-High-Definition 4K TV at full resolution.

That is the kind of difference that Imagin Medical Inc. is bringing to the medical imaging and diagnostics market for the treatment of one of the most widespread and costly forms of disease: bladder cancer.

And that’s why its diagnostic system can revolutionize treatment.

Imagin Medical Inc. is an emerging medical imaging company that we think could make a fortune for investors who take advantage of its early stage development. We view this as a biotech style breakthrough without the many hurdles associated with biotech development and with a direct path to product sales as early as 2019.

Medical Imaging’s New Reality

Just as the other digital technologies have been advancing in leaps and bounds, so too has medical imaging. You’ve probably noticed this everywhere from your dentist’s chair, where x-rays now arrive on the screen, to orthoscopic surgery as an in-patient or even in a small clinic. Medical imaging and the diagnostics that it supports are being totally transformed.

There are powerful, new technologies and techniques that are being adopted almost daily. A select few companies have taken the opportunity to draw on the new capabilities and are developing patented approaches that can forever change the way that diseases are diagnosed and treated.

This is the calling of Imagin Medical Inc. and their i/Blue™ Imaging System for the imaging and treatment of tumors targeting bladder cancer.

You won’t likely know about Imagin Medical yet. Their patented i/Blue™ Imaging System just passed through the prototype stage and is about to go into human testing. For our readers, that’s a good thing. Since it’s not widely known, you can accumulate stock at pennies a share– well before the wider market takes notice and creates demand.

We’ve spelled out why we think the situation is a great opportunity that holds the potential for big profits.

One Hundred Times More Accurate at Visualizing Tumors

Imagin Medical is the developer of the i/Blue™ Imaging System to help detect bladder cancer and reduce its recurrence by dramatically improving the urologist’s ability to visualize, identify and then remove cancerous cells.

Here’s how the technology works:

With the development of compact color video cameras over 30 years, urologists have adopted endoscopes (or cystoscopes) combined with white light and video imaging to visualize the interior of the human bladder in order to detect cancer.

Using this technology, providers established that malignant lesions may not be visible and not detected during endoscopic examination alone. So in 2010, the FDA approved a combination of fluorescing drugs and specialized blue light imaging to improve the visualization of tumors.

Bladder cancer tumor, visualized through an endoscope using white light (left image) and blue light using Photocure’s chemical agent called Cysview®* (right image)

[table id=23 /]

Without question, this method produces better visualization and detection of malignant lesions. However, the available technology has several issues that are slowing the wide adoption of this technology.

The main drawbacks besides an inability to more accurately visualize the tumors, are the time needed to absorb fluorescing drugs and the inability to view multiple perspectives of the bladder at the same time.

Imagin Medical’s i/Blue™ patented computer technology, white light and near-infrared fluorescence overcomes all of these shortfalls.

The company’s approach allows the system to accurately image in less than 15 minutes vs. the one-hour period required to metabolize the drug using conventional fluorescing.

Current imaging technology offers only blue filtered images showing a highlighted fluorescence image of the cancer, but without a precise indication of where it is located in the bladder. To see that, the surgeon needs a white light only view to show the full landscape of the bladder, causing them to have to switch back and forth between the white and blue light images on separate systems.

Imagin Medical’s computer application cleans, reprocesses, blends and displays the image of the bladder and cancer onto a single monitor at the same time.

Most importantly, Imagin’s i/Blue™ system increases sensitivity for detecting the cancer specific contrast agent by 5 orders of magnitude or in terms of visibility, 100,000X.

This advancement in sensitivity is vitally important because it improves the surgeon’s ability to detect even flat cancers and to visualize their margins for more complete removal. Ultimately this can dramatically reduce the risk of recurrence, slowing the progression of the disease.(2)

Simply a Better Solution: Less Invasive, Less Costly, More Effective

Advancements in medical technology are crucial, but if they are impractical or too expensive, they simply won’t find their way into the medical system. It’s a fact.

What’s really exciting about the i/Blue™ System is its ability to improve results, simplify procedures, save time, and save money. And in the healthcare system, that is always going to be a major factor.

With a shorter period to review initial diagnostics (roughly 1/3 previous requirements), the time savings is expected to increase the efficiency of the Operating Room markedly. Since it is minimally invasive, the i/Blue™ System will also enable diagnostic and surgical procedures to be performed in the less expensive physician’s office for follow-up exams.

In the end, the recurring nature of the bladder cancer due to missed or undetected tumor removal has made it the most expensive form out of treatable cancers.

Through more effective diagnostics and vastly improved imaging, the i/Blue™ system can have a profound impact on the outcomes from surgery to remove tumors and thereby seriously reduce the cost of treatment or re-treatment.

The i/Blue™ System is such a giant leap forward in the medical imaging space that it qualifies as a disruptive technology

Heavyweights in The Field Doing What They Do Best

Imagin Medical’s products are based on the technology invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL).

Dr. Demos worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to determine the system’s feasibility.

Imagin Medical has now licensed the technology from LLNL and moved the final stages of development to the University of Rochester Laboratory for Laser Energetics (LLE).

We don’t often detail the backgrounds of management, but in this case we think it’s important to understand the professional level of the team responsible for the current and future path of Imagin Medical and its’ i/Blue™ technology.

Imagin’s management have successfully forwarded numerous products and valuable research to the medical field over their lengthy careers including:

Dr. Stavros G. Demos is the technical advisor to the company. He is a prolific inventor and scholar, as well as a laser materials expert. Companies using his technologies include Muse Microscopy, Near Infrared Imaging, and Biosense/Webster. Dr. Demos holds 20 patents and has published more than 115 scholarly journal articles.

Dr. Stavros is the original inventor of the i/Blue™ system and is continuing to work with Imagin in developing the technology. Imagin has an agreement with UC Davis and the University of Rochester Laboratory for Laser Energetics where Dr. Demos continues to support Imagin’s development team through clinical evaluations and into commercialization.

Dr. Ralph deVere White who serves as Imagin’s Medical Advisor, is one of the world’s foremost authorities on bladder cancer. He has authored more than 300 peer-reviewed scientific articles. He is also the director of the UC Davis Comprehensive Cancer Center and a professor of urology at the university. He will actively consult with the Imagin team about bladder cancer.

Rounding out this impressive group is Dr. Edward Messing, Chief of Urology at the University of Rochester Medical Center.

Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the bladder, prostate, kidney, and other genitourinary organs. He has conducted extensive research in the basic biology of bladder and prostate cancers and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers.

Drs. Demos and deVere White continue to the lead in the guidance of testing and development of the i/Blue™ System. Dr. Messing will sponsor the Clinical Research Study at the

University of Rochester using i/Blue Technology.(3)

Bladder Cancer is the 6^th Largest Cancer Market

Imagin Medical participates in the enormous medical imaging, diagnostics and treatment market. The US spends $4.5 billion per year on imaging alone. The diagnostic imaging segment has seen continual growth based on the increasing number of patients, as well as an increasing demand for minimally invasive surgery, which requires precise imaging.

Increasing investments from public-private organizations; growth in the number of diagnostic imaging centers; rising prevalence of cancer; increasing geriatric population and the subsequent growth in the incidence of various diseases; technological advancements in diagnostic imaging modalities; and increasing preference for minimally invasive treatments all drive the growth of this market.

More specifically, the i/Blue™ System is targeted initially at imaging and treatment of bladder cancer.

This year, an estimated 79,030 adults (60,490 men and 18,540 women) will be diagnosed with bladder cancer in the United States. It is estimated that 16,870 deaths from this disease will occur this year.

The treatment of bladder cancer is the most expensive form of cancer to treat, accounting for cumulative costs of $4 billion or about 3.2% of all cancer care each year. It is the sixth largest market for cancer treatment and yet treatment approaches have not changed significantly over the past 25 years.

Healthcare providers and the medical system are desperately seeking ways to reduce the cost of treatment for bladder cancer and provide better, more effective diagnostics and monitoring, since it often requires multiple treatments and continuous follow up over its course. (4)

Potential for Additional Applications Adds Major Value

While Imagin is initially focusing on the bladder cancer imaging market, the company expects that its dual-light, single-screen imaging system will set new standards of care for doctors and surgeons in detecting many other kinds of cancers and conditions.

These may include laparoscopic (general and gynecology), colorectal and thoracic procedures related to cancer and non-cancerous conditions.

According to Stratistics MRC, the Global Medical Imaging market is accounted for $29.8 billion in 2016 and is expected to reach $45.1 billion by 2022. (5)

The US represents the largest market where each day 10,000 people turn 65 years old. The impact of The Affordable Care Act (“Obamacare”) is also providing access to additional services like imaging for more of the population.

The Asia-Pacific region is the fastest growing area. This region is driven by the massive population base and the many environmental health issues created by rapid industrialization.

China is evolving into a massive market for healthcare products in dire need of effective diagnostics and treatments. This one market alone is a potential gold mine for IME to expand the application of its patented technology.

FEATURE STOCK: FOR COMPARISON

[table id=21 /]

The Winners: Too Late For Mass Gains, But Good To Study

These stocks represent some of the biggest winners in the healthcare sector over the last several years. These are large cap stocks, but they are evidence of just how well the industry has performed as a whole and offer insight into the kind of mammoth companies who could look to acquire a well positioned company like Allied Health Care Products.

[table id=22 /]

Our Recommendation: We Give IME Our Strongest BUY Rating

It’s hard not to be impressed by what you see when drill down into Imagin Medical Inc. This is a pure execution play.

By that we mean, the research and development is all but complete and the technology is proven very effective for diagnostics in treating bladder cancer. This removes massive risk for investors.

Imagin Medical’s i/Blue™ technology is also patented. So the company has the ability to build, license or sell its technology and retain all of the value in what is almost certain to be a disruptive technology.

And speaking of acquisitions, it’s pretty common for medical device companies to grow by acquisition, not organically. We see that as a real possibility as IME goes through its human testing recently announced. A lot of attention will come to the product and company as results are published through the National Institute of Health.

The other major risk factor with emerging medical device or technology companies is having the management needed to “get it done”. By their credentials, the team is truly outstanding. They are leaders in their respective fields who have demonstrated their ability to successfully bring medical devices and new technologies to market before.

The market for the effective treatment of bladder cancer is large and growing worldwide. Imagin Medical can potentially offer one of the only major improvements and cost-effective solutions that the market is seeking right now.

Companies that can deliver breakthroughs for healthcare products and services are expected to continue to be very attractive. That goes for the so called “killer B’s” in our summary (Baxter, B&D and Boston Scientific), and for the small companies with disruptive technologies and a strategic pathway to revenue, including Imagin Medical Inc.

It’s still unknown whether the Trump version of the Affordable Healthcare Act will deliver on the proposed tax cuts that could give the medical device industry a big boost. We will have to wait and see. Based on the industry’s current strong performance, that really doesn’t appear to be a deal breaker.

Let’s face it, if you are dealing with bladder cancer or might face it in the future, you really want Imagin Medical Inc. to succeed. We all might get a big benefit for backing them in the developing stages.

USA News Group
Editorial Staff

Sources:

(1) Imagin Medical news release – https://finance.yahoo.com/news/imagin-medical-receives-approval-1st-212242836.html

(2) Technology efficacy – https://imaginmedical.com/technology/

(3) Clinical Research Study – https://clinicaltrials.gov/ct2/show/NCT03058705?term=imagin+medical&rank=1

(4) The excessive cost of early Stage Bladder Cancer – https://onlinelibrary.wiley.com/store/10.1002/cncr.25227/asset/25227_ftp.pdf;jsessionid=CD2167D8CD074FB3B7C56B4B0F887379.f03t04?v=1&t=j8kvn488&s=7e17361d0151c457c6b8db3bd0137c891c49ecec

(5) Market for Imaging – https://www.marketsandmarkets.com/PressReleases/diagnostic-imaging-market.asp

Disclaimer

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USAnewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Imagin Medical Inc. advertising and digital media. There may be 3rd parties who may have shares of IME, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group does not own any shares of IME.

Blue Light Cystoscopy Increases Bladder Cancer Detection Rate

October 23, 2017 by Staff Editor